Select Publications
Journal articles
2020, 'A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic', Blood, 136, pp. 5 - 5, http://dx.doi.org/10.1182/blood-2020-142209
,2020, 'Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance', Blood, 136, pp. 36 - 38, http://dx.doi.org/10.1182/blood-2020-140665
,2020, 'Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment', Blood, 136, pp. 45 - 47, http://dx.doi.org/10.1182/blood-2020-136164
,2020, 'Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome', Blood, 136, pp. 21 - 21, http://dx.doi.org/10.1182/blood-2020-140636
,2020, 'Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease', Blood, 136, pp. 2 - 3, http://dx.doi.org/10.1182/blood-2020-142281
,2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030
,2020, 'Variable CD341 recovery of cryopreserved allogeneic HPC products: Transplant implications during the COVID-19 pandemic', Blood Advances, 4, pp. 4147 - 4150, http://dx.doi.org/10.1182/bloodadvances.2020002431
,2020, 'Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation', Biology of Blood and Marrow Transplantation, 26, pp. 1711 - 1718, http://dx.doi.org/10.1016/j.bbmt.2020.03.005
,2020, 'Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial', LANCET HAEMATOLOGY, 7, pp. E509 - E522, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000544758900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial', The Lancet Haematology, 7, pp. e511 - e522, http://dx.doi.org/10.1016/S2352-3026(20)30120-4
,2020, 'Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic', Internal Medicine Journal, 50, pp. 667 - 679, http://dx.doi.org/10.1111/imj.14859
,2020, 'Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement', Internal Medicine Journal, 50, pp. 774 - 775, http://dx.doi.org/10.1111/imj.14867
,2020, 'PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor', Value in Health, 23, pp. S479 - S480, http://dx.doi.org/10.1016/j.jval.2020.08.462
,2019, 'Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis', Supportive Care in Cancer, 27, pp. 4451 - 4460, http://dx.doi.org/10.1007/s00520-019-05020-8
,2019, 'An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era', Blood, 134, pp. 5719 - 5719, http://dx.doi.org/10.1182/blood-2019-126547
,2019, 'HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia', Leukemia, 33, pp. 1439 - 1450, http://dx.doi.org/10.1038/s41375-018-0321-8
,2019, 'A case series of langerhans cell histiocytosis with braf testing', Pathology, 51, pp. S92 - S92, http://dx.doi.org/10.1016/j.pathol.2018.12.243
,2019, 'CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS', Hematological Oncology, 37, pp. 535 - 537, http://dx.doi.org/10.1002/hon.221_2631
,2017, 'Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data', European Journal of Haematology, 99, pp. 160 - 168, http://dx.doi.org/10.1111/ejh.12899
,2017, 'Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD', Annals of Hematology, 96, pp. 805 - 815, http://dx.doi.org/10.1007/s00277-017-2939-4
,2016, 'Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia', Journal of Translational Medicine, 14, pp. 82, http://dx.doi.org/10.1186/s12967-016-0837-5
,2015, 'Primary cutaneous mantle-cell lymphoma: A case report and literature review', Journal of Clinical Oncology, 33, pp. e104 - e108, http://dx.doi.org/10.1200/JCO.2012.47.2829
,2015, 'Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation', American Journal of Hematology, 90, pp. 392 - 399, http://dx.doi.org/10.1002/ajh.23955
,2015, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, 168, pp. 350 - 360, http://dx.doi.org/10.1111/bjh.13134
,2015, 'Effectiveness of Iphone's Touch ID: KSA Case Study', INTERNATIONAL JOURNAL OF ADVANCED COMPUTER SCIENCE AND APPLICATIONS, 6, pp. 154 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357578700022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation', Biology of Blood and Marrow Transplantation, 20, pp. 1751 - 1757, http://dx.doi.org/10.1016/j.bbmt.2014.07.001
,2014, 'Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning', Biology of Blood and Marrow Transplantation, 20, pp. 1722 - 1728, http://dx.doi.org/10.1016/j.bbmt.2014.06.033
,2014, 'BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase', American Journal of Hematology, 89, pp. 626 - 632, http://dx.doi.org/10.1002/ajh.23707
,2014, 'Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models', Bone Marrow Transplantation, 49, pp. 649 - 656, http://dx.doi.org/10.1038/bmt.2014.20
,2014, 'Validation of national institutes of health global scoring system for chronic Graft-Versus-Host Disease (GVHD) according to overall and GVHD-specific survival', Biology of Blood and Marrow Transplantation, 20, pp. 556 - 563, http://dx.doi.org/10.1016/j.bbmt.2014.01.010
,2014, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, http://dx.doi.org/10.1111/bjh.13134
,2013, 'Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable', Blood, 122, pp. 4601 - 4601, http://dx.doi.org/10.1182/blood.v122.21.4601.4601
,Conference Papers
2022, 'International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 5225 - 5227, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-165010
,2022, 'Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 4839 - 4842, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-164619
,2021, 'A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies', in BLOOD, AMER SOC HEMATOLOGY, pp. 3868 - +, http://dx.doi.org/10.1182/blood-2021-146602Get
,2020, 'Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/-AntiCD20 Antibody: The Australasian Lymphoma Alliance Experience', in BLOOD, AMER SOC HEMATOLOGY, ELECTR NETWORK, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-138642
,2020, 'Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance', in BLOOD, AMER SOC HEMATOLOGY, ELECTR NETWORK, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-134972
,2020, 'Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study', in BLOOD, AMER SOC HEMATOLOGY, http://dx.doi.org/10.1182/blood-2020-139076
,2020, 'Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study', in BLOOD, AMER SOC HEMATOLOGY, http://dx.doi.org/10.1182/blood-2020-139057
,2020, 'An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation', in BLOOD, AMER SOC HEMATOLOGY, http://dx.doi.org/10.1182/blood-2020-138684
,2020, 'Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study', in BLOOD, AMER SOC HEMATOLOGY, http://dx.doi.org/10.1182/blood-2020-136574
,2020, 'Outcomes of high dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumours from 1999-2019. An Australia and New Zealand (ANZ). registry-based study in collaboration with ABMTRR.', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 45 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'An Electronic Health Record Facilitates a Safer and More Efficient Rural Outreach Haematology/Oncology Service', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-127796
,2019, 'Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-125154
,2019, 'BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000496473200822&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenstrom Macroglobulinaemia/ Lymphoplasmacytic Lymphoma', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, presented at 60th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 01 December 2018 - 04 December 2018, http://dx.doi.org/10.1182/blood-2018-99-113969
,2018, 'Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non GCB Subtypes: The Phase 2b Sadal Study', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, presented at 60th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 01 December 2018 - 04 December 2018, http://dx.doi.org/10.1182/blood-2018-99-116868
,2017, 'Novel Remote Authentication Protocol Using Heart-signals with Chaos Cryptography', in 2017 INTERNATIONAL CONFERENCE ON INFORMATICS, HEALTH & TECHNOLOGY (ICIHT), IEEE, SAUDI ARABIA, Riyadh, presented at International Conference on Informatics, Health and Technology (ICIHT), SAUDI ARABIA, Riyadh, 21 February 2017 - 23 February 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000403395000024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'SINGLE NUCLEOTIDE POLYMORPHISMS IN APOPTOSIS PATHWAY ARE ASSOCIATED WITH RESPONSE TO IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, AUSTRIA, Vienna, pp. 428 - 428, presented at 20th Congress of European-Hematology-Association, AUSTRIA, Vienna, 11 June 2015 - 14 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361204903060&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD', in Bone Marrow Transplantation, pp. 1528 - 1534, http://dx.doi.org/10.1038/bmt.2014.181
,